お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、高度免疫グロブリン製剤の世界市場、容量、生産量、収益、価格の概要を紹介します。2020~2024年の歴史的な市場収益/売上データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別に高度免疫グロブリン製剤市場を分類しています。
本レポートでは世界の高度免疫グロブリン製剤市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：CSL Behring、Grifols、Biotest、Kedrion、Emergent、Kamada、CNBG、Hualan Bio、Shanghai RAAS、CBPO、Sichuan Yuanda Shuyang、ADMA Biologics

レポートは高度免疫グロブリン製剤の主要生産者を調査し、主要地域や国の消費状況も提供します。高度免疫グロブリン製剤の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2020年から2031年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Hepatitis B Immuneglobulins
    Rabies Immuneglobulins
    Tetanus Toxin Immuneglobulins
    Rho(D) Immune Globulin
    Cytomegalovirus Immune Globulin
    Varicella-Zoster Immune Globulin
    Others

用途別の市場セグメント：
    Government Institution
    Private Sector
    Others

本レポートの詳細内容
本レポートは、世界の高度免疫グロブリン製剤市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて高度免疫グロブリン製剤市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2020年から2025年まで、そして2031年までの予測として、メーカー別、地域別（地域レベル、国レベル）の高度免疫グロブリン製剤生産量、成長率、市場シェアを調査している。

二. 消費面では、高度免疫グロブリン製剤の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2020年から2025年まで、2031年までの予測。

三.主要メーカーの高度免疫グロブリン製剤売上高、収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界の高度免疫グロブリン製剤市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本高度免疫グロブリン製剤のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：高度免疫グロブリン製剤のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2020～2031）
第2章： 高度免疫グロブリン製剤の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2020～2031）
第3章：世界、地域、国レベルにおける高度免疫グロブリン製剤の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2020～2031）
第4章高度免疫グロブリン製剤メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2020～2025）
第5章：高度免疫グロブリン製剤の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2020～2031）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2020～2031）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2020～2031）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第12章：高度免疫グロブリン製剤の主要メーカーの概要を提供し、製品の説明と仕様、高度免疫グロブリン製剤の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2020～2025）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：高度免疫グロブリン製剤の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Hyperimmune Globulin is a highly concentrated immunoglobulin containing high levels of specific antibodies used for passive immunotherapy. It is usually extracted from the plasma of recovered patients who have been infected with a specific pathogen, so these people have produced high levels of antibodies against the pathogen.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The global Hyperimmune Globulin Injection market is projected to grow from US$ 2207 million in 2024 to US$ 3205 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.4% during the forecast period.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
Report Includes
This report presents an overview of global market for Hyperimmune Globulin Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Hyperimmune Globulin Injection, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Hyperimmune Globulin Injection, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Hyperimmune Globulin Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Hyperimmune Globulin Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Hyperimmune Globulin Injection sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including CSL Behring, Grifols, Biotest, Kedrion, Emergent, Kamada, CNBG, Hualan Bio, Shanghai RAAS, CBPO, etc.

Market Segmentation
By Company
    CSL Behring
    Grifols
    Biotest
    Kedrion
    Emergent
    Kamada
    CNBG
    Hualan Bio
    Shanghai RAAS
    CBPO
    Sichuan Yuanda Shuyang
    ADMA Biologics

Segment by Type
    Hepatitis B Immuneglobulins
    Rabies Immuneglobulins
    Tetanus Toxin Immuneglobulins
    Rho(D) Immune Globulin
    Cytomegalovirus Immune Globulin
    Varicella-Zoster Immune Globulin
    Others

Segment by Application
    Government Institution
    Private Sector
    Others

Segment by region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia

Middle East, Africa, Latin America
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Hyperimmune Globulin Injection in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Hyperimmune Globulin Injection manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hyperimmune Globulin Injection sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
 Table 1. Global Hyperimmune Globulin Injection Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Table 2. Major Manufacturers of Hepatitis B Immuneglobulins
 Table 3. Major Manufacturers of Rabies Immuneglobulins
 Table 4. Major Manufacturers of Tetanus Toxin Immuneglobulins
 Table 5. Major Manufacturers of Rho(D) Immune Globulin
 Table 6. Major Manufacturers of Cytomegalovirus Immune Globulin
 Table 7. Major Manufacturers of Varicella-Zoster Immune Globulin
 Table 8. Major Manufacturers of Others
 Table 9. Global Hyperimmune Globulin Injection Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Table 10. Global Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 11. Global Hyperimmune Globulin Injection Revenue by Region (2019-2024) & (US$ Million)
 Table 12. Global Hyperimmune Globulin Injection Revenue by Region (2025-2030) & (US$ Million)
 Table 13. Global Hyperimmune Globulin Injection Revenue Market Share by Region (2019-2024)
 Table 14. Global Hyperimmune Globulin Injection Revenue Market Share by Region (2025-2030)
 Table 15. Global Hyperimmune Globulin Injection Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
 Table 16. Global Hyperimmune Globulin Injection Sales by Region (2019-2024) & (K Units)
 Table 17. Global Hyperimmune Globulin Injection Sales by Region (2025-2030) & (K Units)
 Table 18. Global Hyperimmune Globulin Injection Sales Market Share by Region (2019-2024)
 Table 19. Global Hyperimmune Globulin Injection Sales Market Share by Region (2025-2030)
 Table 20. Global Hyperimmune Globulin Injection Sales by Manufacturers (2019-2024) & (K Units)
 Table 21. Global Hyperimmune Globulin Injection Sales Share by Manufacturers (2019-2024)
 Table 22. Global Hyperimmune Globulin Injection Revenue by Manufacturers (2019-2024) & (US$ Million)
 Table 23. Global Hyperimmune Globulin Injection Revenue Market Share by Manufacturers (2019-2024)
 Table 24. Global Key Players of Hyperimmune Globulin Injection, Industry Ranking, 2021 VS 2022 VS 2023
 Table 25. Hyperimmune Globulin Injection Price by Manufacturers (2019-2024) & (US$/Unit)
 Table 26. Global Hyperimmune Globulin Injection Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 27. Global Hyperimmune Globulin Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperimmune Globulin Injection as of 2023)
 Table 28. Global Key Manufacturers of Hyperimmune Globulin Injection, Manufacturing Base Distribution and Headquarters
 Table 29. Global Key Manufacturers of Hyperimmune Globulin Injection, Product Offered and Application
 Table 30. Global Key Manufacturers of Hyperimmune Globulin Injection, Date of Enter into This Industry
 Table 31. Mergers & Acquisitions, Expansion Plans
 Table 32. Global Hyperimmune Globulin Injection Sales by Type (2019-2024) & (K Units)
 Table 33. Global Hyperimmune Globulin Injection Sales by Type (2025-2030) & (K Units)
 Table 34. Global Hyperimmune Globulin Injection Sales Share by Type (2019-2024)
 Table 35. Global Hyperimmune Globulin Injection Sales Share by Type (2025-2030)
 Table 36. Global Hyperimmune Globulin Injection Revenue by Type (2019-2024) & (US$ Million)
 Table 37. Global Hyperimmune Globulin Injection Revenue by Type (2025-2030) & (US$ Million)
 Table 38. Global Hyperimmune Globulin Injection Revenue Share by Type (2019-2024)
 Table 39. Global Hyperimmune Globulin Injection Revenue Share by Type (2025-2030)
 Table 40. Hyperimmune Globulin Injection Price by Type (2019-2024) & (US$/Unit)
 Table 41. Global Hyperimmune Globulin Injection Price Forecast by Type (2025-2030) & (US$/Unit)
 Table 42. Global Hyperimmune Globulin Injection Sales by Application (2019-2024) & (K Units)
 Table 43. Global Hyperimmune Globulin Injection Sales by Application (2025-2030) & (K Units)
 Table 44. Global Hyperimmune Globulin Injection Sales Share by Application (2019-2024)
 Table 45. Global Hyperimmune Globulin Injection Sales Share by Application (2025-2030)
 Table 46. Global Hyperimmune Globulin Injection Revenue by Application (2019-2024) & (US$ Million)
 Table 47. Global Hyperimmune Globulin Injection Revenue by Application (2025-2030) & (US$ Million)
 Table 48. Global Hyperimmune Globulin Injection Revenue Share by Application (2019-2024)
 Table 49. Global Hyperimmune Globulin Injection Revenue Share by Application (2025-2030)
 Table 50. Hyperimmune Globulin Injection Price by Application (2019-2024) & (US$/Unit)
 Table 51. Global Hyperimmune Globulin Injection Price Forecast by Application (2025-2030) & (US$/Unit)
 Table 52. US & Canada Hyperimmune Globulin Injection Sales by Type (2019-2024) & (K Units)
 Table 53. US & Canada Hyperimmune Globulin Injection Sales by Type (2025-2030) & (K Units)
 Table 54. US & Canada Hyperimmune Globulin Injection Revenue by Type (2019-2024) & (US$ Million)
 Table 55. US & Canada Hyperimmune Globulin Injection Revenue by Type (2025-2030) & (US$ Million)
 Table 56. US & Canada Hyperimmune Globulin Injection Sales by Application (2019-2024) & (K Units)
 Table 57. US & Canada Hyperimmune Globulin Injection Sales by Application (2025-2030) & (K Units)
 Table 58. US & Canada Hyperimmune Globulin Injection Revenue by Application (2019-2024) & (US$ Million)
 Table 59. US & Canada Hyperimmune Globulin Injection Revenue by Application (2025-2030) & (US$ Million)
 Table 60. US & Canada Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 61. US & Canada Hyperimmune Globulin Injection Revenue by Country (2019-2024) & (US$ Million)
 Table 62. US & Canada Hyperimmune Globulin Injection Revenue by Country (2025-2030) & (US$ Million)
 Table 63. US & Canada Hyperimmune Globulin Injection Sales by Country (2019-2024) & (K Units)
 Table 64. US & Canada Hyperimmune Globulin Injection Sales by Country (2025-2030) & (K Units)
 Table 65. Europe Hyperimmune Globulin Injection Sales by Type (2019-2024) & (K Units)
 Table 66. Europe Hyperimmune Globulin Injection Sales by Type (2025-2030) & (K Units)
 Table 67. Europe Hyperimmune Globulin Injection Revenue by Type (2019-2024) & (US$ Million)
 Table 68. Europe Hyperimmune Globulin Injection Revenue by Type (2025-2030) & (US$ Million)
 Table 69. Europe Hyperimmune Globulin Injection Sales by Application (2019-2024) & (K Units)
 Table 70. Europe Hyperimmune Globulin Injection Sales by Application (2025-2030) & (K Units)
 Table 71. Europe Hyperimmune Globulin Injection Revenue by Application (2019-2024) & (US$ Million)
 Table 72. Europe Hyperimmune Globulin Injection Revenue by Application (2025-2030) & (US$ Million)
 Table 73. Europe Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 74. Europe Hyperimmune Globulin Injection Revenue by Country (2019-2024) & (US$ Million)
 Table 75. Europe Hyperimmune Globulin Injection Revenue by Country (2025-2030) & (US$ Million)
 Table 76. Europe Hyperimmune Globulin Injection Sales by Country (2019-2024) & (K Units)
 Table 77. Europe Hyperimmune Globulin Injection Sales by Country (2025-2030) & (K Units)
 Table 78. China Hyperimmune Globulin Injection Sales by Type (2019-2024) & (K Units)
 Table 79. China Hyperimmune Globulin Injection Sales by Type (2025-2030) & (K Units)
 Table 80. China Hyperimmune Globulin Injection Revenue by Type (2019-2024) & (US$ Million)
 Table 81. China Hyperimmune Globulin Injection Revenue by Type (2025-2030) & (US$ Million)
 Table 82. China Hyperimmune Globulin Injection Sales by Application (2019-2024) & (K Units)
 Table 83. China Hyperimmune Globulin Injection Sales by Application (2025-2030) & (K Units)
 Table 84. China Hyperimmune Globulin Injection Revenue by Application (2019-2024) & (US$ Million)
 Table 85. China Hyperimmune Globulin Injection Revenue by Application (2025-2030) & (US$ Million)
 Table 86. Asia Hyperimmune Globulin Injection Sales by Type (2019-2024) & (K Units)
 Table 87. Asia Hyperimmune Globulin Injection Sales by Type (2025-2030) & (K Units)
 Table 88. Asia Hyperimmune Globulin Injection Revenue by Type (2019-2024) & (US$ Million)
 Table 89. Asia Hyperimmune Globulin Injection Revenue by Type (2025-2030) & (US$ Million)
 Table 90. Asia Hyperimmune Globulin Injection Sales by Application (2019-2024) & (K Units)
 Table 91. Asia Hyperimmune Globulin Injection Sales by Application (2025-2030) & (K Units)
 Table 92. Asia Hyperimmune Globulin Injection Revenue by Application (2019-2024) & (US$ Million)
 Table 93. Asia Hyperimmune Globulin Injection Revenue by Application (2025-2030) & (US$ Million)
 Table 94. Asia Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 95. Asia Hyperimmune Globulin Injection Revenue by Region (2019-2024) & (US$ Million)
 Table 96. Asia Hyperimmune Globulin Injection Revenue by Region (2025-2030) & (US$ Million)
 Table 97. Asia Hyperimmune Globulin Injection Sales by Region (2019-2024) & (K Units)
 Table 98. Asia Hyperimmune Globulin Injection Sales by Region (2025-2030) & (K Units)
 Table 99. Middle East, Africa and Latin America Hyperimmune Globulin Injection Sales by Type (2019-2024) & (K Units)
 Table 100. Middle East, Africa and Latin America Hyperimmune Globulin Injection Sales by Type (2025-2030) & (K Units)
 Table 101. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue by Type (2019-2024) & (US$ Million)
 Table 102. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue by Type (2025-2030) & (US$ Million)
 Table 103. Middle East, Africa and Latin America Hyperimmune Globulin Injection Sales by Application (2019-2024) & (K Units)
 Table 104. Middle East, Africa and Latin America Hyperimmune Globulin Injection Sales by Application (2025-2030) & (K Units)
 Table 105. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue by Application (2019-2024) & (US$ Million)
 Table 106. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue by Application (2025-2030) & (US$ Million)
 Table 107. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 108. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue by Country (2019-2024) & (US$ Million)
 Table 109. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue by Country (2025-2030) & (US$ Million)
 Table 110. Middle East, Africa and Latin America Hyperimmune Globulin Injection Sales by Country (2019-2024) & (K Units)
 Table 111. Middle East, Africa and Latin America Hyperimmune Globulin Injection Sales by Country (2025-2030) & (K Units)
 Table 112. CSL Behring Company Information
 Table 113. CSL Behring Description and Major Businesses
 Table 114. CSL Behring Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 115. CSL Behring Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 116. CSL Behring Recent Developments
 Table 117. Grifols Company Information
 Table 118. Grifols Description and Major Businesses
 Table 119. Grifols Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 120. Grifols Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 121. Grifols Recent Developments
 Table 122. Biotest Company Information
 Table 123. Biotest Description and Major Businesses
 Table 124. Biotest Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 125. Biotest Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 126. Biotest Recent Developments
 Table 127. Kedrion Company Information
 Table 128. Kedrion Description and Major Businesses
 Table 129. Kedrion Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 130. Kedrion Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 131. Kedrion Recent Developments
 Table 132. Emergent Company Information
 Table 133. Emergent Description and Major Businesses
 Table 134. Emergent Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 135. Emergent Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 136. Emergent Recent Developments
 Table 137. Kamada Company Information
 Table 138. Kamada Description and Major Businesses
 Table 139. Kamada Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 140. Kamada Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 141. Kamada Recent Developments
 Table 142. CNBG Company Information
 Table 143. CNBG Description and Major Businesses
 Table 144. CNBG Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 145. CNBG Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 146. CNBG Recent Developments
 Table 147. Hualan Bio Company Information
 Table 148. Hualan Bio Description and Major Businesses
 Table 149. Hualan Bio Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 150. Hualan Bio Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 151. Hualan Bio Recent Developments
 Table 152. Shanghai RAAS Company Information
 Table 153. Shanghai RAAS Description and Major Businesses
 Table 154. Shanghai RAAS Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 155. Shanghai RAAS Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 156. Shanghai RAAS Recent Developments
 Table 157. CBPO Company Information
 Table 158. CBPO Description and Major Businesses
 Table 159. CBPO Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 160. CBPO Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 161. CBPO Recent Developments
 Table 162. Sichuan Yuanda Shuyang Company Information
 Table 163. Sichuan Yuanda Shuyang Description and Major Businesses
 Table 164. Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 165. Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 166. Sichuan Yuanda Shuyang Recent Developments
 Table 167. ADMA Biologics Company Information
 Table 168. ADMA Biologics Description and Major Businesses
 Table 169. ADMA Biologics Hyperimmune Globulin Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 170. ADMA Biologics Hyperimmune Globulin Injection Product Model Numbers, Pictures, Descriptions and Specifications
 Table 171. ADMA Biologics Recent Developments
 Table 172. Key Raw Materials Lists
 Table 173. Raw Materials Key Suppliers Lists
 Table 174. Hyperimmune Globulin Injection Distributors List
 Table 175. Hyperimmune Globulin Injection Customers List
 Table 176. Hyperimmune Globulin Injection Market Trends
 Table 177. Hyperimmune Globulin Injection Market Drivers
 Table 178. Hyperimmune Globulin Injection Market Challenges
 Table 179. Hyperimmune Globulin Injection Market Restraints
 Table 180. Research Programs/Design for This Report
 Table 181. Key Data Information from Secondary Sources
 Table 182. Key Data Information from Primary Sources


List of Figures
 Figure 1. Hyperimmune Globulin Injection Product Picture
 Figure 2. Global Hyperimmune Globulin Injection Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 3. Global Hyperimmune Globulin Injection Market Share by Type: 2023 & 2030
 Figure 4. Hepatitis B Immuneglobulins Product Picture
 Figure 5. Rabies Immuneglobulins Product Picture
 Figure 6. Tetanus Toxin Immuneglobulins Product Picture
 Figure 7. Rho(D) Immune Globulin Product Picture
 Figure 8. Cytomegalovirus Immune Globulin Product Picture
 Figure 9. Varicella-Zoster Immune Globulin Product Picture
 Figure 10. Others Product Picture
 Figure 11. Global Hyperimmune Globulin Injection Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 12. Global Hyperimmune Globulin Injection Market Share by Application: 2023 & 2030
 Figure 13. Government Institution
 Figure 14. Private Sector
 Figure 15. Others
 Figure 16. Hyperimmune Globulin Injection Report Years Considered
 Figure 17. Global Hyperimmune Globulin Injection Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 18. Global Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 19. Global Hyperimmune Globulin Injection Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Figure 20. Global Hyperimmune Globulin Injection Revenue Market Share by Region in Percentage: 2023 Versus 2030
 Figure 21. Global Hyperimmune Globulin Injection Revenue Market Share by Region (2019-2030)
 Figure 22. Global Hyperimmune Globulin Injection Sales (2019-2030) & (K Units)
 Figure 23. Global Hyperimmune Globulin Injection Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
 Figure 24. Global Hyperimmune Globulin Injection Sales Market Share by Region (2019-2030)
 Figure 25. US & Canada Hyperimmune Globulin Injection Sales YoY (2019-2030) & (K Units)
 Figure 26. US & Canada Hyperimmune Globulin Injection Revenue YoY (2019-2030) & (US$ Million)
 Figure 27. Europe Hyperimmune Globulin Injection Sales YoY (2019-2030) & (K Units)
 Figure 28. Europe Hyperimmune Globulin Injection Revenue YoY (2019-2030) & (US$ Million)
 Figure 29. China Hyperimmune Globulin Injection Sales YoY (2019-2030) & (K Units)
 Figure 30. China Hyperimmune Globulin Injection Revenue YoY (2019-2030) & (US$ Million)
 Figure 31. Asia (excluding China) Hyperimmune Globulin Injection Sales YoY (2019-2030) & (K Units)
 Figure 32. Asia (excluding China) Hyperimmune Globulin Injection Revenue YoY (2019-2030) & (US$ Million)
 Figure 33. Middle East, Africa and Latin America Hyperimmune Globulin Injection Sales YoY (2019-2030) & (K Units)
 Figure 34. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue YoY (2019-2030) & (US$ Million)
 Figure 35. Global Hyperimmune Globulin Injection Sales Share by Manufacturers (2023)
 Figure 36. The Hyperimmune Globulin Injection Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
 Figure 37. Global Hyperimmune Globulin Injection Revenue Share by Manufacturers (2023)
 Figure 38. The Top 5 and 10 Largest Manufacturers of Hyperimmune Globulin Injection in the World: Market Share by Hyperimmune Globulin Injection Revenue in 2023
 Figure 39. Global Hyperimmune Globulin Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 40. Global Hyperimmune Globulin Injection Sales Market Share by Type (2019-2030)
 Figure 41. Global Hyperimmune Globulin Injection Revenue Market Share by Type (2019-2030)
 Figure 42. Global Hyperimmune Globulin Injection Sales Market Share by Application (2019-2030)
 Figure 43. Global Hyperimmune Globulin Injection Revenue Market Share by Application (2019-2030)
 Figure 44. US & Canada Hyperimmune Globulin Injection Sales Market Share by Type (2019-2030)
 Figure 45. US & Canada Hyperimmune Globulin Injection Revenue Market Share by Type (2019-2030)
 Figure 46. US & Canada Hyperimmune Globulin Injection Sales Market Share by Application (2019-2030)
 Figure 47. US & Canada Hyperimmune Globulin Injection Revenue Market Share by Application (2019-2030)
 Figure 48. US & Canada Hyperimmune Globulin Injection Revenue Share by Country (2019-2030)
 Figure 49. US & Canada Hyperimmune Globulin Injection Sales Share by Country (2019-2030)
 Figure 50. US Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 51. Canada Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 52. Europe Hyperimmune Globulin Injection Sales Market Share by Type (2019-2030)
 Figure 53. Europe Hyperimmune Globulin Injection Revenue Market Share by Type (2019-2030)
 Figure 54. Europe Hyperimmune Globulin Injection Sales Market Share by Application (2019-2030)
 Figure 55. Europe Hyperimmune Globulin Injection Revenue Market Share by Application (2019-2030)
 Figure 56. Europe Hyperimmune Globulin Injection Revenue Share by Country (2019-2030)
 Figure 57. Europe Hyperimmune Globulin Injection Sales Share by Country (2019-2030)
 Figure 58. Germany Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 59. France Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 60. U.K. Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 61. Italy Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 62. Russia Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 63. China Hyperimmune Globulin Injection Sales Market Share by Type (2019-2030)
 Figure 64. China Hyperimmune Globulin Injection Revenue Market Share by Type (2019-2030)
 Figure 65. China Hyperimmune Globulin Injection Sales Market Share by Application (2019-2030)
 Figure 66. China Hyperimmune Globulin Injection Revenue Market Share by Application (2019-2030)
 Figure 67. Asia Hyperimmune Globulin Injection Sales Market Share by Type (2019-2030)
 Figure 68. Asia Hyperimmune Globulin Injection Revenue Market Share by Type (2019-2030)
 Figure 69. Asia Hyperimmune Globulin Injection Sales Market Share by Application (2019-2030)
 Figure 70. Asia Hyperimmune Globulin Injection Revenue Market Share by Application (2019-2030)
 Figure 71. Asia Hyperimmune Globulin Injection Revenue Share by Region (2019-2030)
 Figure 72. Asia Hyperimmune Globulin Injection Sales Share by Region (2019-2030)
 Figure 73. Japan Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 74. South Korea Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 75. China Taiwan Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 76. Southeast Asia Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 77. India Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 78. Australia Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 79. Middle East, Africa and Latin America Hyperimmune Globulin Injection Sales Market Share by Type (2019-2030)
 Figure 80. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue Market Share by Type (2019-2030)
 Figure 81. Middle East, Africa and Latin America Hyperimmune Globulin Injection Sales Market Share by Application (2019-2030)
 Figure 82. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue Market Share by Application (2019-2030)
 Figure 83. Middle East, Africa and Latin America Hyperimmune Globulin Injection Revenue Share by Country (2019-2030)
 Figure 84. Middle East, Africa and Latin America Hyperimmune Globulin Injection Sales Share by Country (2019-2030)
 Figure 85. Brazil Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 86. Mexico Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 87. Turkey Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 88. Israel Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 89. GCC Countries Hyperimmune Globulin Injection Revenue (2019-2030) & (US$ Million)
 Figure 90. Hyperimmune Globulin Injection Value Chain
 Figure 91. Hyperimmune Globulin Injection Production Process
 Figure 92. Channels of Distribution (Direct Vs Distribution)
 Figure 93. Bottom-up and Top-down Approaches for This Report
 Figure 94. Data Triangulation
 Figure 95. Key Executives Interviewed